Provided by Tiger Fintech (Singapore) Pte. Ltd.

Olema Pharmaceuticals, Inc.

5.62
+0.33006.24%
Post-market: 5.620.00000.00%16:05 EDT
Volume:983.18K
Turnover:5.51M
Market Cap:384.03M
PE:-2.55
High:5.74
Open:5.35
Low:5.33
Close:5.29
Loading ...

Olema Pharmaceuticals Files Shelf for 2 Equity Offerings

MT Newswires Live
·
07 Jan

BRIEF-Olema Pharmaceuticals Files For Mixed Shelf Of Up To $200 Million - SEC Filing

Reuters
·
07 Jan

Olema Oncology files $200M mixed securities shelf

TIPRANKS
·
07 Jan

Olema Pharmaceuticals Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing

THOMSON REUTERS
·
07 Jan

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Jan

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Jan

Novartis' Gene Therapy Meets Primary Endpoint in SMA Study

Zacks
·
01 Jan

U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart

Reuters
·
17 Dec 2024

Bain Capital Life Sciences Opportunities Iv, L.p. Reports 9.99% Passive Stake in Olema Pharmaceuticals Inc as of Dec 4 - SEC Filing

THOMSON REUTERS
·
12 Dec 2024

Oppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
11 Dec 2024

Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

Olema Pharmaceuticals: Promising Clinical Data and Growth Potential Warrant a Buy Rating

TIPRANKS
·
11 Dec 2024

Olema Pharmaceuticals Advances Breast Cancer Treatments

TIPRANKS
·
10 Dec 2024

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination With Ribociclib at the San Antonio Breast Cancer Symposium

THOMSON REUTERS
·
10 Dec 2024

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

GlobeNewswire
·
10 Dec 2024

Novartis Announces Positive Results From Late-Stage Study on Fabhalta

Zacks
·
10 Dec 2024

Olema Pharmaceuticals Cleared to Begin Testing Prospective Breast Cancer Candidate

MT Newswires Live
·
09 Dec 2024

Olema Pharmaceuticals Shares Rise 8.9% on FDA Approval of Cancer Drug Application

Dow Jones
·
09 Dec 2024

BRIEF-Olema Oncology Announces FDA Clearance Of Investigational New Drug Application For OP-3136

Reuters
·
09 Dec 2024

Olema Pharmaceuticals Inc - Phase 1 Clinical Trial for Op-3136 to Start Early 2025

THOMSON REUTERS
·
09 Dec 2024